<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="4" ids="30225">Positron</z:chebi> emission tomography (PET) imaging allows identification of stress-induced <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and myocardial viability in patients with ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the left ventricular (LV) functional response to <z:chebi fb="1" ids="35620">vasodilator</z:chebi> stress in patients with advanced ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> undergoing pharmacologic stress (PET) perfusion and metabolic imaging </plain></SENT>
<SENT sid="2" pm="."><plain>Additionally, we aimed to determine if <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>), right ventricular (RV) dysfunction and diastolic function influenced the observed LV responses to pharmacologic stress </plain></SENT>
<SENT sid="3" pm="."><plain>In 161 patients (81% men; 65 ± 13 years), PET and echocardiography were performed within a week for noninvasive evaluation of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> and viability (scored using 17-segment model), as well as ventricular and valvular function </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were stratified based on ischemic defects in any segments versus hibernation/scar defects only </plain></SENT>
<SENT sid="5" pm="."><plain>The LV volumes, EF by gating and transient ischemic <z:mpath ids='MPATH_66'>dilatation</z:mpath> (TID) index were generated automatically </plain></SENT>
<SENT sid="6" pm="."><plain>Wall thickening (WT) scores were determined visually </plain></SENT>
<SENT sid="7" pm="."><plain>The subgroup with reversible/ischemic segments on PET imaging (N = 55) exhibited greater end-systolic (ESV) and end-diastolic volume (EDV) enlargement during stress (13 ± 22 and 16 ± 43 ml increase respectively, vs. 0 ± 18 ml [P &lt; 0.0001] and 2 ± 24 ml [P = 0.01]), a decrease in LVEF during stress (mean -3% vs. +2%), and greater TID indices (mean 1.13 ± 0.18 vs. 1.02 ± 0.12) compared to hibernation/scar only (N = 92) </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, mean WT scores during stress declined significantly only in the ischemic subgroup (P &lt; 0.0001 for regional LAD, non-LAD and global wall thickening scores) </plain></SENT>
<SENT sid="9" pm="."><plain>The prevalence and the severity of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> and RV dysfunction did not differ between groups </plain></SENT>
<SENT sid="10" pm="."><plain>By univariate analysis, global and LAD territory segmental <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, global sum stress score (SSS), TID index, resting EF, ESV enlargement during stress, as well as global WT changes correlated with post-stress LVEF decline </plain></SENT>
<SENT sid="11" pm="."><plain>Multivariate predictors included SSS, resting LVEF, and ESV change </plain></SENT>
<SENT sid="12" pm="."><plain>Ischemic changes on <z:chebi fb="1" ids="35620">vasodilator</z:chebi> PET imaging are associated with global LV functional decline and volumetric <z:mpath ids='MPATH_66'>dilatation</z:mpath>, presumably due to stunning effect </plain></SENT>
<SENT sid="13" pm="."><plain>Severity of RV dysfunction and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> had limited impact on the above changes </plain></SENT>
</text></document>